• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Fractyl Health touts 2-year durability study for diabetes reversal procedure

February 1, 2022 By Sean Whooley

Fractyl-Logo-CMYK-June2021-02Fractyl Health today announced that it published two-year durability data from its Revita-1 clinical study in Europe and South America.

Lexington, Massachusetts-based Fractyl’s trial included a two-year follow-up from 34 type 2 diabetes patients who received the company’s Revita duodenal mucosal resurfacing (DMR) procedure.

According to a news release, the study observed no long-term adverse events from Revita in patients with poorly controlled diabetes on oral glucose-lowering medications. HbA1c was observed to be statistically significantly reduced at all time points in the two-year cohort, as were broader measures of metabolic control, including reductions in weight and improvements in patient self-reported diabetes treatment satisfaction questionnaires (DTSQc).

There were no long-term treatment-related adverse events or device- or procedure-related serious adverse events, unanticipated device effects or hypoglycemic events observed between month six and month 24. One patient had mild constipation and another had mild vitamin B12 deficiency.

At 24 months following a single Revita procedure, there was an HbA1c reduction of 1% from baseline, a mean weight reduction of -3.1 kg from baseline and a mean increase of HDL of 6.4, all statistically significant. Diabetes treatment satisfaction was improved based on a statistically significant increase in DTSQc at 24 months, while mean levels of LDL, total cholesterol and triglyceride were not statistically significant from baseline to month 24.

“These results from our earlier REVITA-1 study give an encouraging picture of the potential long-term outcomes of Revita on multiple clinical and patient-relevant parameters, including glucose control, weight change, cardiovascular parameters and patient satisfaction,” Fractyl Health Co-Founder and CEO Dr. Harith Rajagopalan said in the release. “We are committed to rigorously evaluating the safety and effectiveness of Revita in patients with T2D across the spectrum of disease with our Revitalize T2D clinical development program.”

Filed Under: Clinical Trials, Diabetes, Featured Tagged With: Fractyl Health

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS